Furthermore, GH has been identified as a candidate disease-modifying target in non-alcoholic fatty liver disease (NAFLD) because of its lipolytic and anti-inflammatory properties [17,30]. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatotic liver disease.